Bibliographic Citation
| - Reck M., Ciuleanu T.-E., Cobo M., Schenker M., Zurawski B., Menezes J., Richardet E., Bennouna J., Felip E., Juan-Vidal O., Alexandru A., Sakai H., Lingua A., Reyes F., Souquet P.-J., de Marchi P., Martin C., Pérol M., Scherpereel A., Lu S., Paz-Ares L., Carbone D.P., Memaj A., Marimuthu S., Zhang X., Tran P., John T. . First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update . ESMO Open, 2021, 6 (5), pp.100273 . ⟨10.1016/j.esmoop.2021.100273⟩
- Reck M., Ciuleanu T.-E., Cobo M., Schenker M., Zurawski B., Menezes J., Richardet E., Bennouna J., Felip E., Juan-Vidal O., Alexandru A., Sakai H., Lingua A., Reyes F., Souquet P.-J., de Marchi P., Martin C., Pérol M., Scherpereel A., Lu S., Paz-Ares L., Carbone D.P., Memaj A., Marimuthu S., Zhang X., Tran P., John T.. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. ESMO Open, 2021, 6 (5), pp.100273. ⟨10.1016/j.esmoop.2021.100273⟩
|